MetadataShow full item record
Other TitlesMalawi Project 2010-2013
From Multidisciplinary to Transdisciplinary Collaboration in Global Health: A Case Study of the University of Maryland Global Health Interprofessional Council’s Malawi Project (2013)
Safe Motherhood Needs Assessment (2012)
Global Health Inter-Professional Council Summer Interdisciplinary Student Project-Malawi 2011
A Needs Assessment of Orphans & Vulnerable Children (OVCs) in Salima District, Malawi (2010)
DescriptionThe Global Health Interprofessional Council (GHIC) at the University of Maryland Baltimore sponsored students from the seven professional schools on the campus to do studies or provide health related services in Malawi. Included are literature or slide presentations for projects spanning several years since 2010.
University of Maryland, Baltimore
Interdisciplinary approach in education
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/8469
Showing items related by title, author, creator and subject.
Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, MalawiMeiring, J.E.; Laurens, M.B.; Patel, P. (Oxford University Press, 2019)BACKGROUND: Typhoid fever is an acute infection characterized by prolonged fever following the ingestion and subsequent invasion of Salmonella enterica serovar Typhi (S. Typhi), a human-restricted pathogen. The incidence of typhoid fever has been most reported in children 5-15 years of age, but is increasingly recognized in children younger than 5 years old. There has been a recent expansion of multidrug-resistant typhoid fever globally. Prior typhoid vaccines were not suitable for use in the youngest children in countries with a high burden of disease. This study aims to determine the efficacy of a typhoid conjugate vaccine (TCV) that was recently prequalified by the World Health Organization, by testing it in children 9 months through 12 years of age in Blantyre, Malawi. METHODS: In this Phase III, individually randomized, controlled, double-blind trial of the clinical efficacy of TCV, 28 000 children 9 months through 12 years of age will be enrolled and randomized in a 1:1 ratio to receive either Vi-TCV or a meningococcal serogroup A conjugate vaccine. A subset of 600 of these children will be further enrolled in an immunogenicity and reactogenicity sub-study to evaluate the safety profile and immune response elicited by Vi-TCV. Recruiting began in February 2018. RESULTS: All children will be under passive surveillance for at least 2 years to determine the primary outcome, which is blood culture-confirmed S. Typhi illness. Children enrolled in the immunogenicity and reactogenicity sub-study will have blood drawn before vaccination and at 2 timepoints after vaccination to measure their immune response to vaccination. They will also be followed actively for adverse events and serious adverse events. CONCLUSIONS: The introduction of a single-dose, efficacious typhoid vaccine into countries with high burden of disease or significant antimicrobial resistance could have a dramatic impact, protecting children from infection and reducing antimicrobial usage and associated health inequity in the world's poorest places. This trial, the first of a TCV in Africa, seeks to demonstrate the impact and programmatic use of TCVs within an endemic setting. CLINICAL TRIALS REGISTRATION: NCT03299426. © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.